Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Mar-Oseltamivir (02497352), Mar-Oseltamivir (02497360), Mar-Oseltamivir (02497379). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
OSELTAMIVIR PHOSPHATE
Form:
15 of 15 products shown
13 Limited Use · 2 not a benefit
Other products in the same Health Canada class (J05A, J05AH) — coverage varies; not interchangeable
Zanamivir (Relenza): limited Use 414, 415
Abacavir + lamivudine + zidovudine (Trizivir): general benefit
Abacavir (Ziagen): general benefit
Abacavir + lamivudine (Kivexa): general benefit
Acyclovir (Zovirax): general benefit, Not a benefit
Atazanavir (Reyataz): general benefit, Not a benefit
48 more in the class list below
Jamp Oseltamivir · DIN 02497409 · 30mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Oseltamivir · DIN 02497409
Manufacturer: Jamp Pharma Corporation; listing date 2020-11-30
Health Canada: Marketed since 2020-09-24 · brand JAMP OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG · company Jamp pharma corporation · schedule Prescription
Jamp Oseltamivir: Formulary list price $0.5243/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5243 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98723 · Verify on the e-Formulary ↗ (DIN 02497409)
Source record
DIN 02497409: Jamp Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800341; group id 103; item number 0182; lccId 00143; manufacturer id JPC
Source form: Cap; strength: 30mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5243; ministry $0.5243
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497409
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98723Interchangeable products
Mint-Oseltamivir · DIN 02497441 · $0.5243
Nat-Oseltamivir · DIN 02472635 · $0.5243
Sandoz Oseltamivir · DIN 02504006 · $0.5243
Tamiflu · DIN 02304848 · $0.5243
Shortage status: resolved shortage (ended 2026-02-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497409
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Oseltamivir · DIN 02497441 · 30mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Oseltamivir · DIN 02497441
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-08-28
Health Canada: Marketed since 2023-10-18 · brand MINT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Oseltamivir: Formulary list price $0.5243/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5243 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98727 · Verify on the e-Formulary ↗ (DIN 02497441)
Source record
DIN 02497441: Mint-Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800341; group id 103; item number 0182; lccId 00143; manufacturer id MIN
Source form: Cap; strength: 30mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5243; ministry $0.5243
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497441
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98727Interchangeable products
Jamp Oseltamivir · DIN 02497409 · $0.5243
Nat-Oseltamivir · DIN 02472635 · $0.5243
Sandoz Oseltamivir · DIN 02504006 · $0.5243
Tamiflu · DIN 02304848 · $0.5243
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497441
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nat-Oseltamivir · DIN 02472635 · 30mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Oseltamivir · DIN 02472635
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2018-05-31
Health Canada: Marketed since 2018-02-06 · brand NAT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Oseltamivir: Formulary list price $0.5243/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5243 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96194 · Verify on the e-Formulary ↗ (DIN 02472635)
Source record
DIN 02472635: Nat-Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800341; group id 103; item number 0182; lccId 00143; manufacturer id NAT
Source form: Cap; strength: 30mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5243; ministry $0.5243
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472635
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96194Interchangeable products
Jamp Oseltamivir · DIN 02497409 · $0.5243
Mint-Oseltamivir · DIN 02497441 · $0.5243
Sandoz Oseltamivir · DIN 02504006 · $0.5243
Tamiflu · DIN 02304848 · $0.5243
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472635
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Oseltamivir · DIN 02504006 · 30mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Oseltamivir · DIN 02504006
Manufacturer: Sandoz Canada Inc.; listing date 2021-01-29
Health Canada: Marketed since 2025-04-15 · brand SANDOZ OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Oseltamivir: Formulary list price $0.5243/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5243 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99346 · Verify on the e-Formulary ↗ (DIN 02504006)
Source record
DIN 02504006: Sandoz Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800341; group id 103; item number 0182; lccId 00143; manufacturer id SDZ
Source form: Cap; strength: 30mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5243; ministry $0.5243
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504006
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99346Interchangeable products
Jamp Oseltamivir · DIN 02497409 · $0.5243
Mint-Oseltamivir · DIN 02497441 · $0.5243
Nat-Oseltamivir · DIN 02472635 · $0.5243
Tamiflu · DIN 02304848 · $0.5243
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504006
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tamiflu · DIN 02304848 · 30mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Savings card: innoviCares lists Tamiflu (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Tamiflu · DIN 02304848
Manufacturer: Hoffmann-La Roche Limited; listing date 2011-03-15
Health Canada: Marketed since 2008-12-01 · brand TAMIFLU · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG · company Hoffmann-la roche limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79011 · Verify on the e-Formulary ↗ (DIN 02304848)
Source record
DIN 02304848: Tamiflu
Raw flags: sec12=Y, sec3=Y
Item: 081800341; group id 103; item number 0182; lccId 00143; manufacturer id HLR
Source form: Cap; strength: 30mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.1150; ministry $0.5243
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304848
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79011Interchangeable products
Jamp Oseltamivir · DIN 02497409 · $0.5243
Mint-Oseltamivir · DIN 02497441 · $0.5243
Nat-Oseltamivir · DIN 02472635 · $0.5243
Sandoz Oseltamivir · DIN 02504006 · $0.5243
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304848
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nat-Oseltamivir · DIN 02472643 · 45mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Oseltamivir · DIN 02472643
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2018-05-31
Health Canada: Marketed since 2018-02-06 · brand NAT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Oseltamivir: Formulary list price $1.6135/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.6135 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96195 · Verify on the e-Formulary ↗ (DIN 02472643)
Source record
DIN 02472643: Nat-Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800342; group id 103; item number 0183; lccId 00143; manufacturer id NAT
Source form: Cap; strength: 45mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6135; ministry $1.6135
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472643
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96195Interchangeable products
Sandoz Oseltamivir · DIN 02504014 · $1.6135
Tamiflu · DIN 02304856 · $1.6135
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472643
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Oseltamivir · DIN 02504014 · 45mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Oseltamivir · DIN 02504014
Manufacturer: Sandoz Canada Inc.; listing date 2021-01-29
Health Canada: Marketed since 2025-04-15 · brand SANDOZ OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Oseltamivir: Formulary list price $1.6135/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.6135 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99347 · Verify on the e-Formulary ↗ (DIN 02504014)
Source record
DIN 02504014: Sandoz Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800342; group id 103; item number 0183; lccId 00143; manufacturer id SDZ
Source form: Cap; strength: 45mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6135; ministry $1.6135
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504014
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99347Interchangeable products
Nat-Oseltamivir · DIN 02472643 · $1.6135
Tamiflu · DIN 02304856 · $1.6135
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504014
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tamiflu · DIN 02304856 · 45mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Savings card: innoviCares lists Tamiflu (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Tamiflu · DIN 02304856
Manufacturer: Hoffmann-La Roche Limited; listing date 2011-03-15
Health Canada: Marketed since 2008-12-08 · brand TAMIFLU · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG · company Hoffmann-la roche limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79012 · Verify on the e-Formulary ↗ (DIN 02304856)
Source record
DIN 02304856: Tamiflu
Raw flags: sec12=Y, sec3=Y
Item: 081800342; group id 103; item number 0183; lccId 00143; manufacturer id HLR
Source form: Cap; strength: 45mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.2540; ministry $1.6135
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304856
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79012Interchangeable products
Nat-Oseltamivir · DIN 02472643 · $1.6135
Sandoz Oseltamivir · DIN 02504014 · $1.6135
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304856
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Oseltamivir · DIN 02497425 · 75mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Oseltamivir · DIN 02497425
Manufacturer: Jamp Pharma Corporation; listing date 2020-11-30
Health Canada: Marketed since 2020-09-24 · brand JAMP OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG · company Jamp pharma corporation · schedule Prescription
Jamp Oseltamivir: Formulary list price $1.0393/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0393 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98725 · Verify on the e-Formulary ↗ (DIN 02497425)
Source record
DIN 02497425: Jamp Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800064; group id 103; item number 0184; lccId 00143; manufacturer id JPC
Source form: Cap; strength: 75mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.0393; ministry $1.0393
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497425
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98725Interchangeable products
Mint-Oseltamivir · DIN 02497476 · $1.0393
Nat-Oseltamivir · DIN 02457989 · $1.0393
Sandoz Oseltamivir · DIN 02504022 · $1.0393
Tamiflu · DIN 02241472 · $1.0393
Shortage status: resolved shortage (ended 2026-04-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497425
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Oseltamivir · DIN 02497476 · 75mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Oseltamivir · DIN 02497476
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-07-31
Health Canada: Marketed since 2023-10-18 · brand MINT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Oseltamivir: Formulary list price $1.0393/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0393 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98729 · Verify on the e-Formulary ↗ (DIN 02497476)
Source record
DIN 02497476: Mint-Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800064; group id 103; item number 0184; lccId 00143; manufacturer id MIN
Source form: Cap; strength: 75mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.0393; ministry $1.0393
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02497476
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98729Interchangeable products
Jamp Oseltamivir · DIN 02497425 · $1.0393
Nat-Oseltamivir · DIN 02457989 · $1.0393
Sandoz Oseltamivir · DIN 02504022 · $1.0393
Tamiflu · DIN 02241472 · $1.0393
Shortage status: resolved shortage (ended 2023-10-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497476
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nat-Oseltamivir · DIN 02457989 · 75mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Oseltamivir · DIN 02457989
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2016-11-30
Health Canada: Marketed since 2016-09-29 · brand NAT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG · company Natco pharma (canada) inc · schedule Prescription
Nat-Oseltamivir: Formulary list price $1.0393/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0393 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94501 · Verify on the e-Formulary ↗ (DIN 02457989)
Source record
DIN 02457989: Nat-Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800064; group id 103; item number 0184; lccId 00143; manufacturer id NAT
Source form: Cap; strength: 75mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.0393; ministry $1.0393
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457989
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94501Interchangeable products
Jamp Oseltamivir · DIN 02497425 · $1.0393
Mint-Oseltamivir · DIN 02497476 · $1.0393
Sandoz Oseltamivir · DIN 02504022 · $1.0393
Tamiflu · DIN 02241472 · $1.0393
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02457989
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Oseltamivir · DIN 02504022 · 75mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Oseltamivir · DIN 02504022
Manufacturer: Sandoz Canada Inc.; listing date 2021-01-29
Health Canada: Marketed since 2025-04-15 · brand SANDOZ OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Oseltamivir: Formulary list price $1.0393/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0393 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99348 · Verify on the e-Formulary ↗ (DIN 02504022)
Source record
DIN 02504022: Sandoz Oseltamivir
Raw flags: sec12=Y, sec3=Y
Item: 081800064; group id 103; item number 0184; lccId 00143; manufacturer id SDZ
Source form: Cap; strength: 75mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.0393; ministry $1.0393
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504022
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99348Interchangeable products
Jamp Oseltamivir · DIN 02497425 · $1.0393
Mint-Oseltamivir · DIN 02497476 · $1.0393
Nat-Oseltamivir · DIN 02457989 · $1.0393
Tamiflu · DIN 02241472 · $1.0393
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504022
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tamiflu · DIN 02241472 · 75mg · capsule
Limited Use — Reason for Use code 371, 372, 639 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 371, 372, 639 required
Write on scriptLU code 371, 372, 639 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 371, 372, 639
Reason for Use code 371
For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.
Coverage limit:
Network will limit supply to 6 weeks.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 372
For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.
Coverage limit:
Network will limit supply to 5 days.
Coverage limit:
*The outbreak must be confirmed by Public Health.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 639
For treatment of individuals who are at high risk* of complications from influenza infection and have either:
1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection
*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:
- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema
- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease
- Renal disease
- Chronic liver disease
- Diabetes mellitus and other metabolic diseases
- Anemia and hemoglobinopathies, such as sickle cell disease
- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)
- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)
- Children aged younger than 5 years
- Individuals aged 65 years or older
- Individuals of any age who are residents of nursing homes or other chronic care facilities
- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended
- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender
- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid
- Indigenous peoples
Maximum dosage: 75mg twice daily for 5 days
Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.
Coverage limit:
LU Authorization Period: 6 Months
Coverage limit:
Prescribers and dispensers should be informed of the drug product's official indications as set out in Health Canada's approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product's funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.
Savings card: innoviCares lists Tamiflu (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Tamiflu · DIN 02241472
Manufacturer: Hoffmann-La Roche Limited; listing date 2003-04-16
Health Canada: Marketed since 1999-12-23 · brand TAMIFLU · ATC J05AH02 OSELTAMIVIR · form Capsule · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG · company Hoffmann-la roche limited · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65111 · Verify on the e-Formulary ↗ (DIN 02241472)
Source record
DIN 02241472: Tamiflu
Raw flags: sec12=Y, sec3=Y
Item: 081800064; group id 103; item number 0184; lccId 00143; manufacturer id HLR
Source form: Cap; strength: 75mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4.1940; ministry $1.0393
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241472
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65111Interchangeable products
Jamp Oseltamivir · DIN 02497425 · $1.0393
Mint-Oseltamivir · DIN 02497476 · $1.0393
Nat-Oseltamivir · DIN 02457989 · $1.0393
Sandoz Oseltamivir · DIN 02504022 · $1.0393
Shortage status: resolved shortage (ended 2026-02-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02241472
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nat-Oseltamivir · DIN 02499894 · 6mg/mL · oral liquid
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nat-Oseltamivir · DIN 02499894
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-09-29 · brand NAT-OSELTAMIVIR · ATC J05AH02 OSELTAMIVIR · form Powder for suspension · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 6 MG/ML · company Natco pharma (canada) inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98960 · Verify on the e-Formulary ↗ (DIN 02499894)
Source record
DIN 02499894: Nat-Oseltamivir
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800403; group id 104; item number 0185; lccId None; manufacturer id NAT
Source form: O/L; strength: 6mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.2811; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499894
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98960Interchangeable products
Tamiflu · DIN 02381842 · not recorded
Shortage status: active shortage (reported 2025-12-31, estimated to end 2027-04-30, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02499894
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Tamiflu · DIN 02381842 · 6mg/mL · oral liquid
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Tamiflu (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Tamiflu · DIN 02381842
Manufacturer: Hoffmann-La Roche Limited; listing date 2020-08-28
Health Canada: Marketed since 2012-09-10 · brand TAMIFLU · ATC J05AH02 OSELTAMIVIR · form Powder for suspension · route Oral · ingredients OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 6 MG/ML · company Hoffmann-la roche limited · schedule Prescription
Tamiflu: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86768 · Verify on the e-Formulary ↗ (DIN 02381842)
Source record
DIN 02381842: Tamiflu
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081800403; group id 104; item number 0185; lccId None; manufacturer id HLR
Source form: O/L; strength: 6mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381842
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86768Interchangeable products
Nat-Oseltamivir · DIN 02499894 · not recorded
Shortage status: resolved shortage (ended 2026-03-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381842
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered
· 1 products · General benefit · strengths: 800mg & 150mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18
and 42 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
ZANAMIVIR · Limited Use, codes 414, 415
INDICATIONS AND CLINICAL USE
Treatment of Influenza
RELENZA (zanamivir dry powder for inhalation) is indicated for treatment of
uncomplicated acute illness due to influenza A and B virus in adults and pediatric
patients 7 years of age and older, who have been symptomatic for no more than 2 days.
PM: https://pdf.hres.ca/dpd_pm/00046474.PDF; date July 20, 2018; DIN 02240863; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications
TAMIFLU (oseltamivir phosphate, capsules and powder for oral suspension) is indicated for:
• The treatment of uncomplicated acute illness due to influenza infection in adults and adolescents
(≥ 13 years) who have been symptomatic for no more than 2 days.
The treatment indication is based on two Phase III clinical studies of naturally occurring influenza in
adults in which the predominant infection was influenza A (95%) and a limited number with
influenza B (3%) and influenza of unknown type (2%), reflecting the distribution of these strains in
the community. The indication is also supported by influenza A and B challenge studies. No data
are available to support the safety and efficacy of TAMIFLU in adult patients who commenced
treatment after 40 hours of onset of symptoms.
• The treatment of uncomplicated acute illness due to influenza in pediatric patients 1 year and older
who have been symptomatic for no more than 2 days.
The pediatric indication is based on one Phase III clinical study of naturally occurring influenza in
pediatric patients aged 1 to 12 years in which 67% of influenza infected patients were infected wit…
https://pdf.hres.ca/dpd_pm/00085655.PDF
PM date: 2026-08-05
Source product: TAMIFLU; DIN 02241472; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Nat-Oseltamivir · DIN 02499894
Shortage status: active shortage (reported 2025-12-31, estimated to end 2027-04-30, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02499894
For Nat-Oseltamivir, Tamiflu: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.